Low Incidence of Osteonecrosis of the Jaw in Postmenopausal Women With Osteoporosis Taking Zoledronic Acid Once Yearly

Cesar Migliorati

Research output: Contribution to journalComment/debate

2 Citations (Scopus)

Abstract

Article Title and Bibliographic Information: Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. Grbic JT, et al. J Am Dent Assoc 2008;139(1):32-40. Level of Evidence: Level 3: Other evidence. Strength Of Recommendation Grade: Grade C: Consensus, disease-oriented evidence, usual practice, expert opinion, or case series for studies of diagnosis, treatment, prevention or screening. Purpose/Question: What is the incidence of ONJ in women with osteoporosis who received once-yearly infusion of 5 mg of zoledronic acid? Source of Funding: Novartis Pharma AG, Basel, Switzerland, provided financial support and the zoledronic acid used in this study. Type of Study/Design: Three-year international multicenter, randomized, double-blind, placebo-controlled clinical trial.

Original languageEnglish (US)
Pages (from-to)13-15
Number of pages3
JournalJournal of Evidence-Based Dental Practice
Volume9
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

zoledronic acid
Osteonecrosis
Jaw
Osteoporosis
Incidence
Financial Support
Postmenopausal Osteoporosis
Controlled Clinical Trials
Expert Testimony
Switzerland
Placebos
Health

All Science Journal Classification (ASJC) codes

  • Dentistry(all)

Cite this

Low Incidence of Osteonecrosis of the Jaw in Postmenopausal Women With Osteoporosis Taking Zoledronic Acid Once Yearly. / Migliorati, Cesar.

In: Journal of Evidence-Based Dental Practice, Vol. 9, No. 1, 01.01.2009, p. 13-15.

Research output: Contribution to journalComment/debate

@article{568a3b6b04274d699407856151b80b97,
title = "Low Incidence of Osteonecrosis of the Jaw in Postmenopausal Women With Osteoporosis Taking Zoledronic Acid Once Yearly",
abstract = "Article Title and Bibliographic Information: Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. Grbic JT, et al. J Am Dent Assoc 2008;139(1):32-40. Level of Evidence: Level 3: Other evidence. Strength Of Recommendation Grade: Grade C: Consensus, disease-oriented evidence, usual practice, expert opinion, or case series for studies of diagnosis, treatment, prevention or screening. Purpose/Question: What is the incidence of ONJ in women with osteoporosis who received once-yearly infusion of 5 mg of zoledronic acid? Source of Funding: Novartis Pharma AG, Basel, Switzerland, provided financial support and the zoledronic acid used in this study. Type of Study/Design: Three-year international multicenter, randomized, double-blind, placebo-controlled clinical trial.",
author = "Cesar Migliorati",
year = "2009",
month = "1",
day = "1",
doi = "10.1016/j.jebdp.2008.12.014",
language = "English (US)",
volume = "9",
pages = "13--15",
journal = "Journal of Evidence-Based Dental Practice",
issn = "1532-3382",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Low Incidence of Osteonecrosis of the Jaw in Postmenopausal Women With Osteoporosis Taking Zoledronic Acid Once Yearly

AU - Migliorati, Cesar

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Article Title and Bibliographic Information: Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. Grbic JT, et al. J Am Dent Assoc 2008;139(1):32-40. Level of Evidence: Level 3: Other evidence. Strength Of Recommendation Grade: Grade C: Consensus, disease-oriented evidence, usual practice, expert opinion, or case series for studies of diagnosis, treatment, prevention or screening. Purpose/Question: What is the incidence of ONJ in women with osteoporosis who received once-yearly infusion of 5 mg of zoledronic acid? Source of Funding: Novartis Pharma AG, Basel, Switzerland, provided financial support and the zoledronic acid used in this study. Type of Study/Design: Three-year international multicenter, randomized, double-blind, placebo-controlled clinical trial.

AB - Article Title and Bibliographic Information: Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. Grbic JT, et al. J Am Dent Assoc 2008;139(1):32-40. Level of Evidence: Level 3: Other evidence. Strength Of Recommendation Grade: Grade C: Consensus, disease-oriented evidence, usual practice, expert opinion, or case series for studies of diagnosis, treatment, prevention or screening. Purpose/Question: What is the incidence of ONJ in women with osteoporosis who received once-yearly infusion of 5 mg of zoledronic acid? Source of Funding: Novartis Pharma AG, Basel, Switzerland, provided financial support and the zoledronic acid used in this study. Type of Study/Design: Three-year international multicenter, randomized, double-blind, placebo-controlled clinical trial.

UR - http://www.scopus.com/inward/record.url?scp=61349161837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61349161837&partnerID=8YFLogxK

U2 - 10.1016/j.jebdp.2008.12.014

DO - 10.1016/j.jebdp.2008.12.014

M3 - Comment/debate

VL - 9

SP - 13

EP - 15

JO - Journal of Evidence-Based Dental Practice

JF - Journal of Evidence-Based Dental Practice

SN - 1532-3382

IS - 1

ER -